Q-omics provides the consensus-scored FGF7P7 profile across patient tissues and cancer cell-line models. FGF7P7 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, FGF7P7 is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, FGF7P7 RNA expression shows 2,767 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight UCS, LUAD, and PCPG as cancer lineages where FGF7P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FGF7P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FGF7P7 survival associations across molecular data types. FGF7P7 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FGF7P7 RNA expression–survival associations across cancer types. High FGF7P7 expression shows unfavorable associations in UCS, KIRP, BLCA, LUSC and COAD, but favorable associations in SKCM. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for FGF7P7 RNA expression.
This table summarizes FGF7P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for FGF7P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FGF7P7 shows higher tumor expression in LUAD. The LUAD box plot shows higher FGF7P7 RNA expression in tumor versus normal tissue (log2 FC = +0.040, t-test p = .024).
This table shows molecular features associated with FGF7P7 in patient tissues and cancer cell lines. In patient samples, FGF7P7 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set.
